SING GEORGE L sold $1.9M of REGN
SING GEORGE L sold 2,000 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $958.97 ($956.96–$960.26, $1.92M total) across 4 trades over 2026-11-16 to 2026-11-17.
How this was made
The 30-second read
Why it matters
The key new information is the director’s open-market sale details (shares, dates, price range, and total value). This can influence short-term sentiment but does not provide new operational or financial guidance.
Market read
Traders may briefly reassess sentiment around REGN due to director selling, but the filing alone is unlikely to drive a sustained repricing without accompanying fundamental news.
What to watch
The filing does not state motivation, and the sale size, while notable, is not large enough here to imply a change in corporate strategy or near-term fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Regeneron Pharmaceuticals, filed via SEC EDGAR.
Ticker impact
SEC Form 4 shows director Sing George L sold 2,000 REGN shares in open-market trades totaling about $1.92M, under no 10b5-1 plan.
Likely limited near-term pressure as traders weigh the sale against ongoing fundamentals, with most impact confined to sentiment.
The article is a primary insider transaction filing with defined size and timing, but it does not include earnings, guidance, legal/regulatory developments, or operational catalysts.
Market effects
Minimal, as this is company-specific insider activity without sector-wide signal.
None expected beyond typical single-name sentiment effects.
None expected.
Counterpoint
Director sales are often routine liquidity events; without a 10b5-1 plan, the sale could still be unrelated to company outlook.
Key entities
- issuerRegeneron Pharmaceuticals, Inc.
US-listed biotech subject of the Form 4 insider sale disclosure.
- insiderSing George L
Director who sold 2,000 shares across four open-market trades.



